Structure-Activity Relationships of (+)-Naltrexone-Inspired Toll-like Receptor 4 (TLR4) Antagonists

Journal of Medicinal Chemistry

Volumn 58, Issue 12, 2015, Pages 5038-5052

  Selfridge, Brandon R ^a   Wang, Xiaohui ^b   Zhang, Yingning ^b   Yin, Hang ^b   Grace, Peter M ^b   Watkins, Linda R ^b   Jacobson, Arthur E ^a   Rice, Kenner C ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 (CYCLOPROPYLMETHYL) 3 METHOXY 4 PHENOXY 6,7,8,8A,9,10 HEXAHYDRO 5H 9,4B (EPIMINOETHANO) PHENANTHREN 8A OL; 11 (CYCLOPROPYLMETHYL) 3,8A DIHYDROXY 8,8A,9,10 TETRAHYDRO 5H 9,4B (EPIMINOETHANOL)PHENANTHREN 6(7H) ONE; 11 (CYCLOPROPYLMETHYL) 6,7,8,8A,9,10 HEXAHYDRO 5H 9,4B (EPIMINOETHANOL)PHENANTHRENE 3,8A DIOL; 11 HEXYL 3 METHOXY 8,8A,9,10 TETRAHYDRO 7H 9,4B (EPINIMOETHANO)PHENANTHREN 8A OL; 11 HEXYL 6,7,8,8A,9,10 HEXAHYDRO 5H 9,4B (EPIMINOETHANO)PHENANTHRENE 3,8A DIOL; 11 HEXYL 8,8A,9,10 TETRAHYDRO 7H 9,4B (EPIMINOETHANOL)PHENANTHRENE 3,8A DIOL; 3 (2 FLUOROPHENETHYL) 4A,9 DIHYDROXY 2,3,4,4A,5,6 HEXAHYDRO 1H 4,12 METHANOBENZOFURO[3,2 E]ISOQUINOLIN 7(7AH) ONE; 3 (CYCLOPROPYLMETHYL) 2,3,4,4A,5,6,7,7A OCTAHYDRO 1H 4,12 METHANOBENZOFURO[3,2 E]ISOQUINOLINE 4A,7,9 TRIOL; 3 BUTYL 4A,9 DIHYDROXY 2,3,4,4A,5,6 HEXAHYDRO 1H 4,12 METHANOBENZOFURO[3,2 E]ISOQUINOLIN(7AH); 3 HEPTYL 4A,9 DIHYDROXY 2,3,4,4A,5,6 HEXAHYDRO 1H 4,12 METHANOBENZOFURO[3,2 E]ISOQUINOLIN 7 (7AH) ONE; 3 HEXYL 4A HYDROXY 9 METHOXY 2,3,4,4A,5,6 HEXAHYDRO 1H 4,12 METHANOBENZOFURO[3,2 E] ISOQUINOLIN 7(7AH) ONE; 3 HEXYL 4A,9 DIHYDROXY 2,3,4,4A,5,6 HEXAHYDRO 1H 4,12 METHANOBENZOFURO[3,2 E]ISOQUINOLIN 7(7AH) ONE; 4A HYDROXY 9 METHOXY 3 PHENETHYL 2,3,4,4A,5,6, HEXAHYDRO 1H 4,12 METHANOBENZOFURO[3,2 E] ISOQUINOLIN 7(7AH) ONE; 4A,9 DIHYDROXY 3 (3 PHENYLPROPYL) 2,3,4,4A,5,6 HEXAHYDRO 1H 4,12 METHANOBENZOFURO[3,2 E]ISOQUINOLIN 7(7AH) ONE; 4A,9 DIHYDROXY 3 (4 PHENYLBUTYL) 2,3,4,4A,5,6 HEXAHYDRO 1H 4,12 METHANOBENZOFURO[3,2 E]ISOQUINOLIN 7(7AH) ONE; 4A,9 DIHYDROXY 3 (5 PHENYLPENTYL) 2,3,4,4A,5,6 HEXAHYDRO 1H 4,12 METHANOBENZOFURO[3,2 E]ISOQUINOLIN 7(7AH) ONE; 4A,9 DIHYDROXY 3 OCTYL 2,3,4,4A,5,6 HEXAHYDRO 1H 4,12 METHANOBENZOFURO[3,2 E]ISOQUINOLIN 7(7AH) ONE; 4A,9 DIHYDROXY 3 PENTYL 2,3,4,4A,5,6 HEXAHYDRO 1H 4,12 METHANOBENZOFURO[3,2 E]ISOQUINOLIN 7 (7AH) ONE; 4A,9 DIHYDROXY 3 PHENETHYL 2,3,4,4A,5,6 HEXAHYDRO 1H 4,12 METHANOBENZOFURO[3,2 E]ISOQUINOLIN 7(7AH) ONE; LIPOPOLYSACCHARIDE; MORPHINE; NALTREXOL; NALTREXONE; NITRIC OXIDE; NOROXYMORPHONE; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AFFECTING AGENT; UNCLASSIFIED DRUG; MORPHINAN DERIVATIVE; NARCOTIC ANALGESIC AGENT;

ADULT; ANALGESIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ARTICLE; BROMINATION; CELL VIABILITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; HYDROGENATION; HYDROPHOBICITY; IC50; MALE; MICROGLIA; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; DRUG POTENTIATION; HUMAN; IMMUNOLOGY; SPRAGUE DAWLEY RAT;

ANALGESICS, OPIOID; ANIMALS; CELL LINE; DRUG SYNERGISM; HUMANS; LIPOPOLYSACCHARIDES; MALE; MICROGLIA; MORPHINANS; MORPHINE; NALTREXONE; NITRIC OXIDE; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; TOLL-LIKE RECEPTOR 4;

EID: 84933036292     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00426     Document Type: Article

References (40)

1. Takeuchi, O.; Akira, S. Pattern recognition receptors and inflammation Cell 2010, 140, 805-820
2. Yang, H.; Hreggvidsdottir, H. S.; Palmblad, K.; Wang, H.; Ochani, M.; Li, J.; Lu, B.; Chavan, S.; Rosas-Ballina, M.; Al-Abed, Y.; Akira, S.; Bierhaus, A.; Erlandsson-Harris, H.; Andersson, U.; Tracey, K. J. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release Proc. Nat. Acad. Sci. U.S.A. 2010, 107, 11942-11947
3. Wang, X.; Smith, C.; Yin, H. Targeting Toll-like receptors with small molecule agents Chem. Soc. Rev. 2013, 42, 4859-4866
4. Hutchinson, M. R.; Northcutt, A. L.; Hiranita, T.; Wang, X.; Lewis, S. S.; Thomas, J.; van Steeg, K.; Kopajtic, T. A.; Loram, L. C.; Sfregola, C.; Galer, E.; Miles, N. E.; Bland, S. T.; Amat, J.; Rozeske, R. R.; Maslanik, T.; Chapman, T. R.; Strand, K. A.; Fleshner, M.; Bachtell, R. K.; Somogyi, A. A.; Yin, H.; Katz, J. L.; Rice, K. C.; Maier, S. F.; Watkins, L. R. Opioid activation of Toll-like receptor 4 contributes to drug reinforcement J. Neurosci. 2012, 32, 11187-11200
5. Wang, X.; Loram, L. C.; Ramos, K.; de Jesus, A. J.; Thomas, J.; Cheng, K.; Reddy, A.; Somogyi, A. A.; Hutchinson, M. R.; Watkins, L. R.; Yin, H. Morphine activates neuroinflammation in a manner parallel to endotoxin Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 6325-6330
6. Wang, X.; Grace, P. M.; Pham, M. N.; Cheng, K.; Strand, K. A.; Smith, C.; Li, J.; Watkins, L. R.; Yin, H. Rifampin inhibits Toll-like receptor 4 signaling by targeting myeloid differentiation protein 2 and attenuates neuropathic pain FASEB J. 2013, 27, 2713-2722
7. Ji, R.-R.; Xu, Z.-Z.; Gao, Y.-J. Emerging targets in neuroinflammation-driven chronic pain Nat. Rev. Drug Discovery 2014, 13, 533-548
8. Grace, P. M.; Hutchinson, M. R.; Maier, S. F.; Watkins, L. R. Pathological pain and the neuroimmune interface Nat. Rev. Immunol. 2014, 14, 217-231
9. Coller, J. K.; Hutchinson, M. R. Implications of central immune signaling caused by drugs of abuse: Mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence Pharmacol. Ther. 2012, 134, 219-245
10. Hutchinson, M. R.; Shavit, Y.; Grace, P. M.; Rice, K. C.; Maier, S. F.; Watkins, L. R. Exploring the neuroimmunopharmacology of opioids: An integrative review of mechanisms of central immune signaling and their implications for opioid analgesia Pharmacol. Rev. 2011, 63, 772-810
11. Hutchinson, M. R.; Bland, S. T.; Johnson, K. W.; Rice, K. C.; Maier, S. F.; Watkins, L. R. Opioid-induced glial activation: Mechanisms of activation and implications for opioid analgesia, dependence, and reward Sci. World J. 2007, 7, 98-111
12. Bachtell, R. K.; Hutchinson, M. R.; Wang, X.; Rice, K.; Maier, S. F.; Watkins, L. R. Targeting the toll of drug abuse: The translational potential of toll-like receptor 4. CNS Neurol. Disord.: Drug Targets [Online early access]. Published Online: May 29, 2015.
13. Wang, X.; Zhang, Y.; Hutchinson, M. R.; Rice, K. C.; Yin, H.; Watkins, L. R. Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as Toll-like receptor 4 antagonists. Br. J. Pharmacol., submitted.
14. Hutchinson, M. R.; Zhang, Y.; Brown, K.; Coats, B. D.; Shridhar, M.; Sholar, P. W.; Patel, S. J.; Crysdale, N. Y.; Harrison, J. A.; Maier, S. F.; Rice, K. C.; Watkins, L. R. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of Toll-like receptor 4 (TLR4) Eur. J. Neurosci. 2008, 28, 20-29
15. Rice, K. C.; Newman, A. H. Total synthesis of northebaine, normorphine, noroxymorphone enantiomers and derivatives via N -Nor intermediates US 5,668,285, 1997.
16. Iijima, I.; Minamikawa, J.; Rice, K. C.; Jacobson, A. E. Synthesis and antinociceptive activity of 7-methoxycodeine J. Med. Chem. 1978, 21, 1320-1322
17. Theberge, F. R.; Li, X.; Kambhampati, S.; Pickens, C. L.; St. Laurent, R.; Bossert, J. M.; Baumann, M. H.; Hutchinson, M. R.; Rice, K. C.; Watkins, L. R.; Shaham, Y. Effect of chronic delivery of the Toll-like receptor 4 antagonist (+)-naltrexone on incubation of heroin craving Biol. Psychiatry 2013, 73, 729-737
18. Northcutt, A.; Hutchinson, M.; Wang, X.; Baratta, M. V.; Hiranita, T.; Cochran, T. A.; Pomerenze, M. B.; Galer, E.; Kopajtic, T. A.; Li, C. M.; Amat, J.; Larsen, G.; Cooper, D. C.; Huang, Y.; O'Neill, C. E.; Yin, H.; Zahniser, N. R.; Katz, J. L.; Rice, K. C.; Maier, S. F.; Bachtell, R. K.; Watkins, L. R. DAT isn't all that: cocaine reward and reinforcement require Toll-like receptor 4 signaling Mol. Psychiatry 2014, 10.1038/mp.2014.177
19. Selfridge, B.; Deschamps, J.; Jacobson, A.; Rice, K. Synthesis of enantiopure 10-nornaltrexones in the search for Toll-like receptor 4 antagonists and opioid ligands J. Org. Chem. 2014, 79, 5007-18
20. Rapoport, H.; Lovell, C. H.; Reist, H. R.; Warren, M. E. The synthesis of thebaine and northebaine from codeinone dimethyl ketal J. Am. Chem. Soc. 1967, 89, 1942-1947
21. Iijima, I.; Minamikawa, J.; Jacobson, A. E.; Brossi, A.; Rice, K. C. Studies in the (+)-morphinan series. 5. Synthesis and biological properties of (+)-naloxone J. Med. Chem. 1978, 21, 398-400
22. de Costa, B. R.; Iadarola, M. J.; Rothman, R. B.; Berman, K. F.; George, C.; Newman, A. H.; Mahboubi, A.; Jacobson, A. E.; Rice, K. C. Probes for narcotic receptor mediated phenomena. 18. Epimeric 6α-iodo-3,14-dihydroxy-17-(cyclopropylmethyl)-4,5α-epoxymorphinans and 6β-iodo-3,14-dihydroxy-17-(cyclopropylmethyl)-4,5α-epoxymorphinans as potential ligands for opioid receptor single photon emission computed tomography-synthesis, evaluation, and radiochemistry of 125I-6β-iodo-3,14-dihydroxy-17-(cyclopropylmethyl)-4,5-epoxymorphinan J. Med. Chem. 1992, 35, 2826-2835
23. Neumann, H.; Wekerle, H. Brain microglia: Watchdogs with pedigree Nat. Neurosci. 2013, 16, 253-255
24. Hutchinson, M. R.; Watkins, L. R. Why is neuroimmunopharmacology crucial for the future of addiction research? Neuropharmacology 2014, 76 (Part B) 218-227
25. Henn, A.; Lund, S.; Hedtjärn, M.; Schrattenholz, A.; Pörzgen, P.; Leist, M. The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation ALTEX 2009, 26, 83-94
26. Schmidtko, A.; Tegeder, I.; Geisslinger, G. No NO, no pain? The role of nitric oxide and cGMP in spinal pain processing Trends Neurosci. 2009, 32, 339-346
27. Tayfun Uzbay, I.; Oglesby, M. W. Nitric oxide and substance dependence Neurosci. Biobehav. Rev. 2001, 25, 43-52
28. Toda, N.; Kishioka, S.; Hatano, Y.; Toda, H. Modulation of opioid actions by nitric oxide signaling Anesthesiology 2009, 110, 166-181
29. Misko, T. P.; Schilling, R. J.; Salvemini, D.; Moore, W. M.; Currie, M. G. A fluorometric assay for the measurement of nitrite in biological samples Anal. Biochem. 1993, 214, 11-16
30. Nagase, H.; Watanabe, A.; Harada, M.; Nakajima, M.; Hasebe, K.; Mochizuki, H.; Yoza, K.; Fujii, H. Novel synthesis of a 1,3,5-trioxazatriquinane skeleton using a nitrogen clamp Org. Lett. 2008, 11, 539-542
31. Nagase, H.; Yamamoto, N.; Nemoto, T.; Yoza, K.; Kamiya, K.; Hirono, S.; Momen, S.; Izumimoto, N.; Hasebe, K.; Mochizuki, H.; Fujii, H. Synthesis of a stable iminium salt and propellane derivatives J. Org. Chem. 2008, 73, 8093-8096
32. Wu, H.; Thatcher, L. N.; Bernard, D.; Parrish, D. A.; Deschamps, J. R.; Rice, K. C.; MacKerell, A. D.; Coop, A. Position of coordination of the lithium ion determines the regioselectivity of demethylations of 3,4-dimethoxymorphinans with L-selectride Org. Lett. 2005, 7, 2531-2534
33. Park, B. S.; Song, D. H.; Kim, H. M.; Choi, B.-S.; Lee, H.; Lee, J.-O. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex Nature 2009, 458, 1191-1195
34. Furrow, M. E.; Myers, A. G. Practical procedures for the preparation of N-tert -butyldimethylsilylhydrazones and their use in modified Wolff-Kishner reductions and in the synthesis of vinyl halides and gem-dihalides J. Am. Chem. Soc. 2004, 126, 5436-5445
35. Hargreaves, K.; Dubner, R.; Brown, F.; Flores, C.; Joris, J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia Pain 1988, 32, 77-88
36. Hutchinson, M. R.; Zhang, Y.; Shridhar, M.; Evans, J. H.; Buchanan, M. M.; Zhao, T. X.; Slivka, P. F.; Coats, B. D.; Rezvani, N.; Wieseler, J.; Hughes, T. S.; Landgraf, K. E.; Chan, S.; Fong, S.; Phipps, S.; Falke, J. J.; Leinwand, L. A.; Maier, S. F.; Yin, H.; Rice, K. C.; Watkins, L. R. Evidence that opioids may have Toll-like receptor 4 and MD-2 effects Brain, Behav., Immun. 2010, 24, 83-95
37. Watkins, L. R.; Wang, X.; Mustafa, S.; Hutchinson, M. R. In vivo veritas: (+)-Naltrexone's actions define translational importance: A letter in response to Skolnick et al. "Translational potential of naloxone and naltrexone as TLR4 antagonists" Trends Pharmacol. Sci. 2014, 35, 432-433
38. Skolnick, P.; Davis, H.; Arnelle, D.; Deaver, D. Translational potential of naloxone and naltrexone as TLR4 antagonists Trends Pharmacol. Sci. 2014, 35, 431-432
39. Milligan, E. D.; Hinde, J. L.; Mehmert, K. K.; Maier, S. F.; Watkins, L. R. A method for increasing the viability of the external portion of lumbar catheters placed in the spinal subarachnoid space of rats J. Neurosci. Methods 1999, 90, 81-86
40. Wu, H. F.; Bernard, D.; Chen, W. B.; Strahan, G. D.; Deschamps, J. R.; Parrish, D. A.; Lewis, J. W.; MacKerell, A. D.; Coop, A. Functionalization of the 6,14-bridge of the orvinols. 2. Preparation of 18- and 19-hydroxyl-substituted thevinols and their treatment with benzyl bromide J. Org. Chem. 2005, 70, 1907-1910